1857-P: Modified Mesenchymal Stromal Cells: A Novel and Safe Therapy for Treating Nonalcoholic Fatty Liver Disease (NAFLD) in Obesity and Diabetes
Background: Mesenchymal stromal cells (MSCs) can home-in to inflamed fat depots to deliver antioxidants locally and help reduce oxidative stress, inflammation and improve NAFLD in high-fat diet (HFD) induced obese (DIO) diabetic mice. Methods: Antioxidants Sod2 (mitochondrial), Catalase (cytosolic)...
Gespeichert in:
| Veröffentlicht in: | Diabetes (New York, N.Y.) N.Y.), 2019-06, Vol.68 (Supplement_1) |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | Supplement_1 |
| container_start_page | |
| container_title | Diabetes (New York, N.Y.) |
| container_volume | 68 |
| creator | DOMINGUES, CLEYTON C. KUNDU, NABANITA KROPOTOVA, YANA SEN, SABYASACHI |
| description | Background: Mesenchymal stromal cells (MSCs) can home-in to inflamed fat depots to deliver antioxidants locally and help reduce oxidative stress, inflammation and improve NAFLD in high-fat diet (HFD) induced obese (DIO) diabetic mice.
Methods: Antioxidants Sod2 (mitochondrial), Catalase (cytosolic) or Null (control) genes were upregulated individually, or in combination in adipose-derived MSCs. Modified MSCs were examined in-vitro in presence of adipogenic media to mimic DIO milieu. Next, modified MSCs were delivered intraperitoneally (IP) in mice that received 45% or 60% HFD for 8 to16 weeks.
Results: In-vitro, we noted reduced MSC lipid droplets with SOD2, Catalase and combination compared to Null. Inflammatory marker IL6 mRNA, was down-regulated in SOD2, Cat and combination MSCs vs. Null-MSCs. In-vivo, n=4, Glucose tolerance test (GTT) improved with SOD2 MSC delivery in (p=0.07) at week-4. Plasma inflammatory marker TNFa, was reduced in both SOD2 and Catalase MSC groups (p |
| doi_str_mv | 10.2337/db19-1857-P |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2248396029</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2248396029</sourcerecordid><originalsourceid>FETCH-LOGICAL-c649-bce4bc12890905ceee269fa45a43b1b0c4ac4066712624e015825c9efd3a8c63</originalsourceid><addsrcrecordid>eNotkMtKw0AYhQdRsFZXvsCAG0Wic8tluiutVSG9QLtwFyaTP3ZKmqkzaSGv4RObUDmLs_k4HD6E7il5YZzHr0VOZUCTMA5WF2hAJZcBZ_HXJRoQQllAYxlfoxvvd4SQqMsA_Z7pEZ7bwpQGCjwHD7XetntV4XXjbN8TqCo_wmO8sCeosKoLvFYl4M0WnDq0uLQObxyoxtTfHVOrStutrYzGM9U0LU7NCRyeGg_KA35cjGfp9AmbGi9z8KYD-sWpUTk04G_RVakqD3f_PUTr2dtm8hGky_fPyTgNdCRkkGsQuaYskUSSUAMAi2SpRKgEz2lOtFBakCiKKYuYAELDhIVaQllwleiID9HDefXg7M8RfJPt7NF1z33GmEi4jAiTHfV8prSz3jsos4Mze-XajJKsV571yrNeYrbif8KOcsY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2248396029</pqid></control><display><type>article</type><title>1857-P: Modified Mesenchymal Stromal Cells: A Novel and Safe Therapy for Treating Nonalcoholic Fatty Liver Disease (NAFLD) in Obesity and Diabetes</title><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>DOMINGUES, CLEYTON C. ; KUNDU, NABANITA ; KROPOTOVA, YANA ; SEN, SABYASACHI</creator><creatorcontrib>DOMINGUES, CLEYTON C. ; KUNDU, NABANITA ; KROPOTOVA, YANA ; SEN, SABYASACHI</creatorcontrib><description>Background: Mesenchymal stromal cells (MSCs) can home-in to inflamed fat depots to deliver antioxidants locally and help reduce oxidative stress, inflammation and improve NAFLD in high-fat diet (HFD) induced obese (DIO) diabetic mice.
Methods: Antioxidants Sod2 (mitochondrial), Catalase (cytosolic) or Null (control) genes were upregulated individually, or in combination in adipose-derived MSCs. Modified MSCs were examined in-vitro in presence of adipogenic media to mimic DIO milieu. Next, modified MSCs were delivered intraperitoneally (IP) in mice that received 45% or 60% HFD for 8 to16 weeks.
Results: In-vitro, we noted reduced MSC lipid droplets with SOD2, Catalase and combination compared to Null. Inflammatory marker IL6 mRNA, was down-regulated in SOD2, Cat and combination MSCs vs. Null-MSCs. In-vivo, n=4, Glucose tolerance test (GTT) improved with SOD2 MSC delivery in (p=0.07) at week-4. Plasma inflammatory marker TNFa, was reduced in both SOD2 and Catalase MSC groups (p<0.05) vs. Null-MSCs group. Analysis of omental and pericardial fat showed significant up-regulation in mRNA expression of brown fat marker, Ucp1 (∼1000 and 100-fold, respectively) and PGC1A mRNA was upregulated. Increased Ucp1 was confirmed by staining. There was a reduction in liver fat content by histology and liver triglyceride assay (p<0.05). Outcome measures of SOD2+Catalase combination MSC delivery in-vivo is pending.
Conclusion: Upregulation of SOD2 plus Catalase, in-vitro, reduced inflammation in adipogenic media more so than individual gene upregulation. In-vivo, delivery of Sod2 and Catalase upregulated individually in MSCs, reduced inflammation and improved GTT with concomitant increased browning of white fat and reduced liver fat. Our results indicate that antioxidant upregulated modified MSC delivery IP, to target inflamed fat depots helps reduce oxidative stress and inflammation and can be an efficient tool for treating obesity, diabetes and NAFLD.</description><identifier>ISSN: 0012-1797</identifier><identifier>EISSN: 1939-327X</identifier><identifier>DOI: 10.2337/db19-1857-P</identifier><language>eng</language><publisher>New York: American Diabetes Association</publisher><subject>Antioxidants ; Body fat ; Catalase ; Diabetes ; Diabetes mellitus ; Fatty liver ; Gene expression ; Glucose tolerance ; High fat diet ; Inflammation ; Interleukin 6 ; Liver ; Liver diseases ; Mesenchymal stem cells ; Mesenchyme ; Mitochondria ; Obesity ; Oxidative stress ; Stromal cells ; Superoxide dismutase ; Tumor necrosis factor-α</subject><ispartof>Diabetes (New York, N.Y.), 2019-06, Vol.68 (Supplement_1)</ispartof><rights>Copyright American Diabetes Association Jun 1, 2019</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>DOMINGUES, CLEYTON C.</creatorcontrib><creatorcontrib>KUNDU, NABANITA</creatorcontrib><creatorcontrib>KROPOTOVA, YANA</creatorcontrib><creatorcontrib>SEN, SABYASACHI</creatorcontrib><title>1857-P: Modified Mesenchymal Stromal Cells: A Novel and Safe Therapy for Treating Nonalcoholic Fatty Liver Disease (NAFLD) in Obesity and Diabetes</title><title>Diabetes (New York, N.Y.)</title><description>Background: Mesenchymal stromal cells (MSCs) can home-in to inflamed fat depots to deliver antioxidants locally and help reduce oxidative stress, inflammation and improve NAFLD in high-fat diet (HFD) induced obese (DIO) diabetic mice.
Methods: Antioxidants Sod2 (mitochondrial), Catalase (cytosolic) or Null (control) genes were upregulated individually, or in combination in adipose-derived MSCs. Modified MSCs were examined in-vitro in presence of adipogenic media to mimic DIO milieu. Next, modified MSCs were delivered intraperitoneally (IP) in mice that received 45% or 60% HFD for 8 to16 weeks.
Results: In-vitro, we noted reduced MSC lipid droplets with SOD2, Catalase and combination compared to Null. Inflammatory marker IL6 mRNA, was down-regulated in SOD2, Cat and combination MSCs vs. Null-MSCs. In-vivo, n=4, Glucose tolerance test (GTT) improved with SOD2 MSC delivery in (p=0.07) at week-4. Plasma inflammatory marker TNFa, was reduced in both SOD2 and Catalase MSC groups (p<0.05) vs. Null-MSCs group. Analysis of omental and pericardial fat showed significant up-regulation in mRNA expression of brown fat marker, Ucp1 (∼1000 and 100-fold, respectively) and PGC1A mRNA was upregulated. Increased Ucp1 was confirmed by staining. There was a reduction in liver fat content by histology and liver triglyceride assay (p<0.05). Outcome measures of SOD2+Catalase combination MSC delivery in-vivo is pending.
Conclusion: Upregulation of SOD2 plus Catalase, in-vitro, reduced inflammation in adipogenic media more so than individual gene upregulation. In-vivo, delivery of Sod2 and Catalase upregulated individually in MSCs, reduced inflammation and improved GTT with concomitant increased browning of white fat and reduced liver fat. Our results indicate that antioxidant upregulated modified MSC delivery IP, to target inflamed fat depots helps reduce oxidative stress and inflammation and can be an efficient tool for treating obesity, diabetes and NAFLD.</description><subject>Antioxidants</subject><subject>Body fat</subject><subject>Catalase</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Fatty liver</subject><subject>Gene expression</subject><subject>Glucose tolerance</subject><subject>High fat diet</subject><subject>Inflammation</subject><subject>Interleukin 6</subject><subject>Liver</subject><subject>Liver diseases</subject><subject>Mesenchymal stem cells</subject><subject>Mesenchyme</subject><subject>Mitochondria</subject><subject>Obesity</subject><subject>Oxidative stress</subject><subject>Stromal cells</subject><subject>Superoxide dismutase</subject><subject>Tumor necrosis factor-α</subject><issn>0012-1797</issn><issn>1939-327X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNotkMtKw0AYhQdRsFZXvsCAG0Wic8tluiutVSG9QLtwFyaTP3ZKmqkzaSGv4RObUDmLs_k4HD6E7il5YZzHr0VOZUCTMA5WF2hAJZcBZ_HXJRoQQllAYxlfoxvvd4SQqMsA_Z7pEZ7bwpQGCjwHD7XetntV4XXjbN8TqCo_wmO8sCeosKoLvFYl4M0WnDq0uLQObxyoxtTfHVOrStutrYzGM9U0LU7NCRyeGg_KA35cjGfp9AmbGi9z8KYD-sWpUTk04G_RVakqD3f_PUTr2dtm8hGky_fPyTgNdCRkkGsQuaYskUSSUAMAi2SpRKgEz2lOtFBakCiKKYuYAELDhIVaQllwleiID9HDefXg7M8RfJPt7NF1z33GmEi4jAiTHfV8prSz3jsos4Mze-XajJKsV571yrNeYrbif8KOcsY</recordid><startdate>20190601</startdate><enddate>20190601</enddate><creator>DOMINGUES, CLEYTON C.</creator><creator>KUNDU, NABANITA</creator><creator>KROPOTOVA, YANA</creator><creator>SEN, SABYASACHI</creator><general>American Diabetes Association</general><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20190601</creationdate><title>1857-P: Modified Mesenchymal Stromal Cells: A Novel and Safe Therapy for Treating Nonalcoholic Fatty Liver Disease (NAFLD) in Obesity and Diabetes</title><author>DOMINGUES, CLEYTON C. ; KUNDU, NABANITA ; KROPOTOVA, YANA ; SEN, SABYASACHI</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c649-bce4bc12890905ceee269fa45a43b1b0c4ac4066712624e015825c9efd3a8c63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Antioxidants</topic><topic>Body fat</topic><topic>Catalase</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Fatty liver</topic><topic>Gene expression</topic><topic>Glucose tolerance</topic><topic>High fat diet</topic><topic>Inflammation</topic><topic>Interleukin 6</topic><topic>Liver</topic><topic>Liver diseases</topic><topic>Mesenchymal stem cells</topic><topic>Mesenchyme</topic><topic>Mitochondria</topic><topic>Obesity</topic><topic>Oxidative stress</topic><topic>Stromal cells</topic><topic>Superoxide dismutase</topic><topic>Tumor necrosis factor-α</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>DOMINGUES, CLEYTON C.</creatorcontrib><creatorcontrib>KUNDU, NABANITA</creatorcontrib><creatorcontrib>KROPOTOVA, YANA</creatorcontrib><creatorcontrib>SEN, SABYASACHI</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>Diabetes (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>DOMINGUES, CLEYTON C.</au><au>KUNDU, NABANITA</au><au>KROPOTOVA, YANA</au><au>SEN, SABYASACHI</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>1857-P: Modified Mesenchymal Stromal Cells: A Novel and Safe Therapy for Treating Nonalcoholic Fatty Liver Disease (NAFLD) in Obesity and Diabetes</atitle><jtitle>Diabetes (New York, N.Y.)</jtitle><date>2019-06-01</date><risdate>2019</risdate><volume>68</volume><issue>Supplement_1</issue><issn>0012-1797</issn><eissn>1939-327X</eissn><abstract>Background: Mesenchymal stromal cells (MSCs) can home-in to inflamed fat depots to deliver antioxidants locally and help reduce oxidative stress, inflammation and improve NAFLD in high-fat diet (HFD) induced obese (DIO) diabetic mice.
Methods: Antioxidants Sod2 (mitochondrial), Catalase (cytosolic) or Null (control) genes were upregulated individually, or in combination in adipose-derived MSCs. Modified MSCs were examined in-vitro in presence of adipogenic media to mimic DIO milieu. Next, modified MSCs were delivered intraperitoneally (IP) in mice that received 45% or 60% HFD for 8 to16 weeks.
Results: In-vitro, we noted reduced MSC lipid droplets with SOD2, Catalase and combination compared to Null. Inflammatory marker IL6 mRNA, was down-regulated in SOD2, Cat and combination MSCs vs. Null-MSCs. In-vivo, n=4, Glucose tolerance test (GTT) improved with SOD2 MSC delivery in (p=0.07) at week-4. Plasma inflammatory marker TNFa, was reduced in both SOD2 and Catalase MSC groups (p<0.05) vs. Null-MSCs group. Analysis of omental and pericardial fat showed significant up-regulation in mRNA expression of brown fat marker, Ucp1 (∼1000 and 100-fold, respectively) and PGC1A mRNA was upregulated. Increased Ucp1 was confirmed by staining. There was a reduction in liver fat content by histology and liver triglyceride assay (p<0.05). Outcome measures of SOD2+Catalase combination MSC delivery in-vivo is pending.
Conclusion: Upregulation of SOD2 plus Catalase, in-vitro, reduced inflammation in adipogenic media more so than individual gene upregulation. In-vivo, delivery of Sod2 and Catalase upregulated individually in MSCs, reduced inflammation and improved GTT with concomitant increased browning of white fat and reduced liver fat. Our results indicate that antioxidant upregulated modified MSC delivery IP, to target inflamed fat depots helps reduce oxidative stress and inflammation and can be an efficient tool for treating obesity, diabetes and NAFLD.</abstract><cop>New York</cop><pub>American Diabetes Association</pub><doi>10.2337/db19-1857-P</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0012-1797 |
| ispartof | Diabetes (New York, N.Y.), 2019-06, Vol.68 (Supplement_1) |
| issn | 0012-1797 1939-327X |
| language | eng |
| recordid | cdi_proquest_journals_2248396029 |
| source | EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Antioxidants Body fat Catalase Diabetes Diabetes mellitus Fatty liver Gene expression Glucose tolerance High fat diet Inflammation Interleukin 6 Liver Liver diseases Mesenchymal stem cells Mesenchyme Mitochondria Obesity Oxidative stress Stromal cells Superoxide dismutase Tumor necrosis factor-α |
| title | 1857-P: Modified Mesenchymal Stromal Cells: A Novel and Safe Therapy for Treating Nonalcoholic Fatty Liver Disease (NAFLD) in Obesity and Diabetes |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T05%3A43%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=1857-P:%20Modified%20Mesenchymal%20Stromal%20Cells:%20A%20Novel%20and%20Safe%20Therapy%20for%20Treating%20Nonalcoholic%20Fatty%20Liver%20Disease%20(NAFLD)%20in%20Obesity%20and%20Diabetes&rft.jtitle=Diabetes%20(New%20York,%20N.Y.)&rft.au=DOMINGUES,%20CLEYTON%20C.&rft.date=2019-06-01&rft.volume=68&rft.issue=Supplement_1&rft.issn=0012-1797&rft.eissn=1939-327X&rft_id=info:doi/10.2337/db19-1857-P&rft_dat=%3Cproquest_cross%3E2248396029%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2248396029&rft_id=info:pmid/&rfr_iscdi=true |